Whither COVID-19 vaccines?

Nat Biotechnol. 2020 Oct;38(10):1132-1145. doi: 10.1038/s41587-020-0697-7.

Abstract

Nature Biotechnology convenes a group of experts to provide their insights into SARS-CoV-2 vaccines in development.

Publication types

  • Interview

MeSH terms

  • Animals
  • Betacoronavirus* / genetics
  • Betacoronavirus* / immunology
  • Biotechnology
  • COVID-19
  • COVID-19 Vaccines
  • Clinical Trials, Phase III as Topic
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control*
  • Coronavirus Infections / virology
  • Disease Models, Animal
  • Drug Development / methods
  • Drug Development / trends
  • Genetic Vectors
  • Global Health
  • Host Microbial Interactions / immunology
  • Humans
  • Immunity, Cellular
  • Immunity, Herd
  • Immunity, Humoral
  • Pandemics / prevention & control*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / prevention & control*
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Safety
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology
  • Translational Research, Biomedical
  • Vaccines, DNA / genetics
  • Vaccines, DNA / isolation & purification
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / isolation & purification
  • Viral Vaccines* / administration & dosage
  • Viral Vaccines* / isolation & purification
  • Viral Vaccines* / standards

Substances

  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • Vaccines, DNA
  • Vaccines, Synthetic
  • Viral Vaccines
  • spike protein, SARS-CoV-2